-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Compilenewborn
On April 20, Johnson & Johnson released its first quarter 2021 performance report, with sales of 22.
Sales in the US market were 11.
International market sales amounted to 11.
After excluding the net impact of acquisitions, divestitures, and exchange rate conversions, based on business operations, global sales increased by 3.
Divided by business, sales of consumer health care business were US$3.
In the first quarter report, Johnson & Johnson raised the adjusted annual operating sales growth guidance value for 2021 to 9.
In terms of the pharmaceutical business, divided by disease areas, immunology sales were 3.
Among them, a number of drugs in the immunology business performed strongly, including Stelara (increased by 9.
In the pulmonary hypertension business, Opsumit and Uptravi performed strongly, increasing by 18.
In the report, Johnson & Johnson also counted the pipeline and business updates in the first quarter of 2021:
- Regulatory approval: Ponvory was approved by the FDA for the treatment of relapsing multiple sclerosis; the single-dose COVID-19 vaccine was approved by the EU, included in the emergency use list by the WHO, and granted emergency use by the US FDA; Spravato was approved by the EU for use Severe depression patients with psychiatric emergencies quickly relieve depression; single-focus intraocular lenses TECNIS EYHANCE and TECNIS EYHANCE TORIC II IOLS have been approved by the US FDA for the treatment of cataracts.
-Regulatory submission: ViiV submitted a supplementary application to the US FDA to expand the use of Cabenuva as an HIV treatment drug every 2 months.
——Other: An update to the Phase 3 ACIS study evaluating Erleada combined with Zytiga and prednisone in the treatment of castration-resistant prostate cancer (mCRPC) patients; and the African Vaccine Access Trust (AVAT) reached a single-dose COVID-19 vaccine purchase Agreement; Ponvory's treatment of relapsing multiple sclerosis received positive opinions from EU CHMP; CAR-T cell therapy cilta-cel was accepted in Europe and included in the accelerated evaluation for the treatment of multiple myeloma.
Reference source: Johnson & Johnson Reports 2021 First-Quarter Results
